Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS
participants through inhibition of inflammatory activity.
Investigators aim to:
Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical
disease activity after 16 weeks of treatment.
Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through
translational analyses of skin biopsy samples.
The primary efficacy measure is the proportion of participants that achieve HiSCR at Week 16
with topical ruxolitinib 1.5% cream as compared to Week 0. The HiSCR is defined as an at
least a 50% reduction in the total abscess and inflammatory nodule count (AN count) for all
study body sites with no increase in abscess count and no increase in draining fistula count
relative to Baseline. The primary efficacy analysis will be carried out on all participants
who complete 16 weeks of treatment.
The research study consists of an 8 week screening with 16 weeks open-label portion.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.